NANOG and colorectal carcinoma: It is therefore pertinent to assess whether OC disrupts this signaling axis by treating primary CRC stem cells (CD133+/CD44+) with OC in the presence or absence of the PAR-2 agonist SLIGRL-NH2, followed by an evaluation of stemness markers (OCT4, NANOG) and organoid-forming capacity.